Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.
Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT02419755
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM
- Conditions
- Interventions
- First Posted Date
- 2015-03-02
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT02375555
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2015-02-25
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 9
- Registration Number
- NCT02370693
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2015-02-12
- Last Posted Date
- 2016-04-20
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 236
- Registration Number
- NCT02362165
- Locations
- 🇨🇳
Sun Yat-sen university cancer center, Guangzhou, Guangdong, China
Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma
- First Posted Date
- 2015-02-05
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 58
- Registration Number
- NCT02356458
- Locations
- 🇨🇭
Kantonsspital Aarau, Aarau, Switzerland
🇮🇹European Institute of Oncology, Milano, Italy
🇨🇭Kantonsspital - St. Gallen, St. Gallen, Switzerland
Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2015-02-02
- Last Posted Date
- 2015-03-09
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 3
- Registration Number
- NCT02353468
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
- First Posted Date
- 2015-02-02
- Last Posted Date
- 2015-03-09
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 3
- Registration Number
- NCT02353572
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2015-02-02
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02352558
- Locations
- 🇺🇸
Virginia Oncology Associates, Norfolk, Virginia, United States
🇺🇸West Clinic, Germantown, Tennessee, United States
🇺🇸Northwest Cancer Specialists, PC, Vancouver, Washington, United States
Bortezomib With Steroid Pulse Therapy for Acute Cellular Rejection in Kidney Transplantation
- First Posted Date
- 2015-01-30
- Last Posted Date
- 2015-02-04
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT02351427
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Selinexor and Backbone Treatments of Multiple Myeloma Patients
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 300
- Registration Number
- NCT02343042
- Locations
- 🇺🇸
Sarah Cannon-Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.